Interpace Biosciences (IDXG)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.11 mm	2.11 mm	2.11 mm	2.11 mm	2.11 mm	2.11 mm
Cash burn (monthly)	(no burn)	243.25 k	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	n/a	1.23 mm	n/a	n/a	n/a	n/a
Cash remaining	n/a	881.00 k	n/a	n/a	n/a	n/a
Runway (months of cash)	n/a	3.6	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

IDXG institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	2	2	–
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	66.97 mm	66.97 mm	–
Total shares	7.83 mm	7.83 mm	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ampersand 2018 Limited Partnership	4.67 mm	$39.90 mm	0.0%
1315 Capital II	3.17 mm	$27.08 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
1315 Capital II	3.17 mm	0.00	0.0%
Ampersand 2018 Limited Partnership	4.67 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IDXG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Oct 24	Ampersand 2018 Limited Partnership	Series C Convertible Preferred Stock Common Stock	Grant	Acquire A	Yes	No	2.02	28,000	56.56 k	28,000
11 Oct 24	Ampersand 2018 Limited Partnership	Series B Convertible Preferred Stock Common Stock	Sale back to company	Acquire D	Yes	No	6	28,000	168.00 k	0
11 Oct 24	1315 Capital II	Series C Convertible Preferred Stock Common Stock	Grant	Acquire A	Yes	No	2.02	19,000	38.38 k	19,000
11 Oct 24	1315 Capital II	Series B Convertible Preferred Stock Common Stock	Sale back to company	Acquire D	Yes	No	6	19,000	114.00 k	0
1 Feb 24	Christopher McCarthy	Common Stock	Grant	Acquire A	No	No	0	10,000	0.00	45,644

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

31 Jan 25

●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc.

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

27 Jan 25

PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced notification that the Centers for

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

9 Jan 25

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today responded to the final Local Coverage